Evidence map›Paper›PMID 34780561›Full record

ArticlePloS one2021

Leucine rich amelogenin peptide prevents ovariectomy-induced bone loss in mice.

Naoto Haruyama, Takayoshi Yamaza, Shigeki Suzuki, Bradford Hall, Andrew Cho, Carolyn W Gibson, Ashok B Kulkarni

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Naoto HaruyamaNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, United States of America.ORCID 0000-0001-6225-5816
Takayoshi YamazaSection of Molecular Cell Biology and Oral Anatomy, Faculty of Dental Science, Kyushu University, Fukuoka-shi, Fukuoka, Japan.
Shigeki SuzukiNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, United States of America.
Bradford HallNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, United States of America.
Andrew ChoNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, United States of America.
Carolyn W GibsonDepartment of Basic and Translational Sciences, University of Pennsylvania School of Dental Medicine, Philadelphia, PA, United States of America.
Ashok B KulkarniNational Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, United States of America.ORCID 0000-0001-9849-3250
National Institutes of Health · USKyushu University · JPUniversity of Pennsylvania · US

Funding

Molecular Roles of Cdk5 in Neuronal Functions and Pain SignalingZIADE000664 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI KULKARNI, ASHOK · 2009 to 2025
$20.4M
Intramural NIH HHS ZIA DE000664
6 · The paper itself

Abstract

Amelogenins, major extra cellular matrix proteins of developing tooth enamel, are predominantly expressed by ameloblasts and play significant roles in the formation of enamel. Recently, amelogenin has been detected in various epithelial and mesenchymal tissues, implicating that it might have distinct functions in various tissues. We have previously reported that leucine rich amelogenin peptide (LRAP), one of the alternate splice forms of amelogenin, regulates receptor activator of NF-kappa B ligand (RANKL) expression in cementoblast/periodontal ligament cells, suggesting that the amelogenins, especially LRAP, might function as a signaling molecule in bone metabolism. The objective of this study was to identify and define LRAP functions in bone turnover. We engineered transgenic (TgLRAP) mice using a murine 2.3kb α1(I)-collagen promoter to drive expression of a transgene consisting of LRAP, an internal ribosome entry site (IRES) and enhanced green fluorescent protein (EGFP) to study functions of LRAP in bone formation and resorption. Calvarial cell cultures from the TgLRAP mice showed increased alkaline phosphatase (ALP) activity and increased formation of mineralized nodules compared to the cells derived from wild-type (WT) mice. The TgLRAP calvarial cells also showed an inhibitory effect on osteoclastogenesis in vitro. Gene expression comparison by quantitative polymerase chain reaction (Q-PCR) in calvarial cells indicated that bone formation makers such as Runx2, Alp, and osteocalcin were increased in TgLRAP compared to the WT cells. Meanwhile, Rankl expression was decreased in the TgLRAP cells in vitro. The ovariectomized (OVX) TgLRAP mice resisted bone loss induced by ovariectomy resulting in higher bone mineral density in comparison to OVX WT mice. The quantitative analysis of calcein intakes indicated that the ovariectomy resulted in increased bone formation in both WT and TgLRAP mice; OVX TgLRAP appeared to show the most remarkably increased bone formation. The parameters for bone resorption in tissue sections showed increased number of osteoclasts in OVX WT, but not in OVX TgLRAP over that of sham operated WT or TgLRAP mice, supporting the observed bone phenotypes in OVX mice. This is the first report identifying that LRAP, one of the amelogenin splice variants, affects bone turnover in vivo.

Indexed as

AnimalsBone DensityBone ResorptionCells, CulturedCollagen Type I, alpha 1 ChainDental Enamel ProteinsFemaleFluoresceinsGreen Fluorescent ProteinsInternal Ribosome Entry SitesMiceMice, TransgenicOsteoblastsOsteogenesisOvariectomyPromoter Regions, GeneticCol1a1 protein, mouseCollagen Type I, alpha 1 ChainDental Enamel ProteinsFluoresceinsfluorexonGreen Fluorescent ProteinsInternal Ribosome Entry Sitesleucine-rich amelogenin peptide

Identifiers

PMID34780561
PMCPMC8592471
OpenAlexW3212944079

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.